Clinical Trial

" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 21, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).
Trial Details
NCT Number NCT06983756
Lead Sponsor Fayoum University
Conditions Erythropoietin Resistant Anemia (EPO Resistant Anemia)
Enrollment 66 participants
Start Date 2025-06-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-21